Impact of COVID-19 on Universal Tumor Screening, Referral Rates and Attendance at Cancer Genetic Counseling at a Safety-Net University Hospital
Current Oncology · 2025
DOI: 10.3390/curroncol32100549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Dimitrios N Varvoglis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: COVID-19, Referral and Consultation, Genetic Counseling, Early Detection of Cancer. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Universal tumor screening (UTS) of all newly diagnosed colorectal cancers (CRCs) for the identification of Lynch syndrome (LS) is recommended. We explored the impact of the COVID-19 pandemic on the UTS process in a safety-net university hospital to identify areas of vulnerability and opportunities for improvement. Patients undergoing resection of a primary CRC were categorized into three cohorts based on surgery date relative to the pandemic (pre-[2018,2019], early-[2020,2021] and late-[2022]). Data regarding (1) UTS performance of immunohistochemistry (IHC) for LS genes and microsatellite instability (MSI) testing; (2) referrals to cancer genetic counseling (CGC) based on mismatch repair deficient (dMMR) status and/or age < 50 years at diagnosis; (3) attendance at CGC; and (4) reasons for not attending CGC were extracted. Between 2018 and 2022, 342 patients underwent resection of a CRC. During the three time periods (pre-, early- and late-pandemic), 93%, 94% and 96% of cases were screened with at least MMR IHC, respectively. Of the patients eligible for referral to CGC in each time period, 60%, 71% and 63% had a referral submitted. Of these, 23%, 36% and 20% in each time period did not attend CGC, with the most common reason for not attending being the inability of schedulers to reach the patient. Although the COVID-19 pandemic did not cause significant variation in the different steps of the UTS process, CGC utilization remained suboptimal throughout the three time periods. Further research on barriers preventing physicians from referring patients to CGC as well as schedulers inability to reach eligible patients should be pursued.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Pharmacy, University of North Carolina Health Care, Chapel Hill, NC 27599, USA.
- Department of Surgery, Penn State University College of Medicine, Hershey, PA 17033, USA.
ORCID-Profile: Dimitrios N Varvoglis, Kelsey R Landrum, Lydia H Comer, Julianne M O'Daniel, Chris B Agala, Lacey M Lee, José G Guillem
Zitieren
APA
Varvoglis, D. N., Landrum, K. R., Comer, L. H., O'Daniel, J. M., Agala, C. B., Lee, L. M., & Guillem, J. G. (2025). Impact of COVID-19 on Universal Tumor Screening, Referral Rates and Attendance at Cancer Genetic Counseling at a Safety-Net University Hospital. Current Oncology. https://doi.org/10.3390/curroncol32100549
Vancouver
Varvoglis DN, Landrum KR, Comer LH, O'Daniel JM, Agala CB, Lee LM, et al. Impact of COVID-19 on Universal Tumor Screening, Referral Rates and Attendance at Cancer Genetic Counseling at a Safety-Net University Hospital. Current Oncology. 2025. doi:10.3390/curroncol32100549
BibTeX
@article{Varvoglis2025,
author = {Varvoglis, Dimitrios N and Landrum, Kelsey R and Comer, Lydia H and O'Daniel, Julianne M and Agala, Chris B and Lee, Lacey M and Guillem, José G},
title = {Impact of COVID-19 on Universal Tumor Screening, Referral Rates and Attendance at Cancer Genetic Counseling at a Safety-Net University Hospital},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32100549}
}
EUVIMED